Probability of rash related to gabapentin therapy in a child

Annals of Pharmacotherapy

Volumn 43, Issue 2, 2009, Pages 387-389

  Gijsen, Violette M G J ^a   De Wildt, Saskia N ^b,c   Ito, Shinya ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b Clinical Pharmacology ^*  (Netherlands)

^c SOPHIA CHILDREN S HOSPITAL   (Netherlands)

Author keywords

Adverse effects; Exanthema; Gabapentin; Pediatrics

Indexed keywords

CHLORAL HYDRATE; CITALOPRAM; CLONAZEPAM; DIPHENHYDRAMINE; GABAPENTIN; METHYLPREDNISOLONE; VALPROIC ACID;

ARTICLE; BEHAVIOR DISORDER; CASE REPORT; CHILD; DEGENERATIVE DISEASE; DRUG ERUPTION; DRUG WITHDRAWAL; EPILEPSY; HUMAN; INSOMNIA; IRRITABILITY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; STOMACH TUBE; TREATMENT OUTCOME; TREATMENT RESPONSE;

AMINES; ANTICONVULSANTS; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSY; EXANTHEMA; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; URTICARIA;

EID: 60349090073     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1L354     Document Type: Article

References (17)

1. Product monograph. Neurontin (gabapentin). Kirkland, Québec: Pfizer Canada Inc., April 2008.
2. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008;22:27-47.
3. Holmes GL. Gabapentin for treatment of epilepsy in children. Semin Pediatr Neurol 1997;4:244-50.
4. Chadwick DW, Anhut H, Greiner MJ, et al. A double-blind trial of gabapentin monotherapy for newly diagnosed partial seizures. International Gabapentin Monotherapy Study Group 945-77. Neurology 1998;51:1282-8.
5. Vieta E, Martinez-Arán A, Nieto E, et al. Adjunctive gabapentin treatment of bipolar disorder. Eur Psychiatry 2000;15:433-7.
6. Korn-Merker E, Borusiak P, Boenigk HE. Gabapentin in childhood epilepsy: a prospective evaluation of efficacy and safety. Epilepsy Res 2000;38:27-32.
7. Arif H, Buchsbaum R, Weintraub D, et al. Comparison and predictors of rash associated with 15 antiepileptic drugs. Neurology 2007;68:1701-9.
8. McDonald DGM, Najam Y, Keegan MB, et al. The use of lamotrigine, vigabatrin and gabapentin as add-on therapy in intractable epilepsy of childhood. Seizure 2005;14:112-6.
9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.
10. Wilton LV, Shakir S. A postmarketing surveillance study of gabapentin as add-on therapy for 3,100 patients in England. Epilepsia 2002;43:983-92.
11. Acharya NV, Pickering RM, Wilton LW, Shakir SAW. The safety and effectiveness of newer antiepileptics: a comparative postmarketing cohort study. J Clin Pharmacol 2005;45:385-93.
12. Gonzalez-Sicilia L, Cano A, Serrano M, Hernandez J. Stevens-Johnson syndrome associated with gabapentin (letter). Am J Med 1998;105:455.
13. DeToledo JC, Minagar A, Lowe MR, Ramsay RE. Skin eruption with gabapentin in a patient with repeated AED -induced Stevens-Johnson's syndrome. Ther Drug Monit 1999;21:137-8.
14. Khurana DS, Riviello J, Helmers S, et al. Efficacy of gabapentin therapy in children with refractory partial seizures. J Pediatr 1996;128:829-33.
15. Wolf SM, Shinnar S, Kang H, Gil KB, Moshé SL. Gabapentin toxicity in children manifesting as behavioral changes. Epilepsia 1995;36:1203-5.
16. Arnold LM, Goldenberg DL, Stanford SB, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007;56:1336-44.
17. Appleton R, Fichtner K, LaMoreaux L, et al. Gabapentin as add-on therapy in children with refractory partial seizures: a 24-week, multicentre, open-label study. Dev Med Child Neurol 2001;43:269-73.